V 512Alternative Names: Influenza virus vaccine - Merck; V512
Latest Information Update: 23 Mar 2010
At a glance
- Originator Merck & Co
- Class Bacterial vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Influenza virus infections
Most Recent Events
- 29 Jan 2008 Phase-I development is ongoing
- 31 Aug 2005 Phase-I clinical trials in Influenza virus infections in USA (unspecified route)